Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, Kentucky.
Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, Kentucky.
JACC Cardiovasc Interv. 2018 Sep 24;11(18):1862-1868. doi: 10.1016/j.jcin.2018.05.033. Epub 2018 Aug 29.
This study sought to evaluate the impact of chronic thrombocytopenia (cTCP) on clinical outcomes after percutaneous coronary intervention (PCI).
The impact of cTCP on clinical outcomes after PCI is not well described. Results from single-center observational studies and subgroup analysis of randomized trials have been conflicting and these patients are either excluded or under-represented in randomized controlled trials.
Using the 2012 to 2014 National (Nationwide) Inpatient Sample database, the study identified patients who underwent PCI with or without cTCP as a chronic condition variable indicator. Propensity score matching was performed using logistic regression to control for differences in baseline characteristics. The primary outcome of interest was in-hospital mortality. Secondary outcomes of interest included in-hospital post-PCI bleeding events, post-PCI blood and platelet transfusion, vascular complications, ischemic cerebrovascular accidents (CVAs), hemorrhagic CVAs, and length of stay.
Propensity matching yielded a cohort of 65,130 patients (32,565 with and without cTCP). Compared with those without cTCP, PCI in patients with cTCP was associated with higher risk for bleeding complications (odds ratio [OR]: 2.40; 95% confidence interval [CI]: 2.05 to 2.72; p < 0.0001), requiring blood transfusion (OR: 2.10; 95% CI: 1.80 to 2.24; p < 0.0001), requiring platelet transfusion (OR: 11.70; 95% CI: 6.00 to 22.60; p < 0.0001), higher risk for vascular complications (OR: 1.94; 95% CI: 1.43 to 2.63; p < 0.0001), ischemic CVA (OR: 1.60; 95% CI: 1.20 to 2.10; p = 0.01), and higher in-hospital mortality (OR: 2.30; 95% CI: 1.90 to 2.70; p < 0.0001), but without a significant difference in hemorrhagic CVA (OR: 1.50; 95% CI: 0.70 to 3.10; p = 0.27).
In this large contemporary cohort, patients with cTCP were at higher risk of a multitude of complications, including higher risk of in-hospital mortality.
本研究旨在评估慢性血小板减少症(cTCP)对经皮冠状动脉介入治疗(PCI)后临床结局的影响。
cTCP 对 PCI 后临床结局的影响尚未得到很好的描述。来自单中心观察性研究和随机试验亚组分析的结果相互矛盾,这些患者要么被排除在随机对照试验之外,要么代表性不足。
利用 2012 年至 2014 年全国(全国范围)住院患者样本数据库,本研究确定了作为慢性疾病变量指标行 PCI 伴或不伴 cTCP 的患者。采用逻辑回归进行倾向评分匹配,以控制基线特征的差异。主要研究终点为住院期间死亡率。次要研究终点包括住院期间 PCI 后出血事件、PCI 后输血和血小板输注、血管并发症、缺血性脑血管意外(CVA)、出血性 CVA 和住院时间。
倾向匹配产生了 65130 例患者队列(32565 例伴有和不伴有 cTCP)。与无 cTCP 相比,cTCP 患者行 PCI 后发生出血并发症的风险更高(比值比 [OR]:2.40;95%置信区间 [CI]:2.05 至 2.72;p<0.0001),需要输血(OR:2.10;95%CI:1.80 至 2.24;p<0.0001),需要血小板输注(OR:11.70;95%CI:6.00 至 22.60;p<0.0001),血管并发症风险更高(OR:1.94;95%CI:1.43 至 2.63;p<0.0001),缺血性 CVA(OR:1.60;95%CI:1.20 至 2.10;p=0.01),住院期间死亡率更高(OR:2.30;95%CI:1.90 至 2.70;p<0.0001),但出血性 CVA 无显著差异(OR:1.50;95%CI:0.70 至 3.10;p=0.27)。
在这项大型当代队列研究中,cTCP 患者发生多种并发症的风险更高,包括住院期间死亡率升高。